摘要
目的探讨阿尼西坦改善慢性精神分裂症患者认知功能的疗效。方法将64例慢性精神分裂症患者随机分为研究组32例和治疗组32例,分别予以奎的平(350±50)mg/d治疗8周,研究组同时合并阿尼西坦100mg/d,并于治疗前及治疗后分别进行阳性和阴性症状量表(PANSS)、简明精神状态量表(MMSE)、中国修订韦氏成人智力量表(WAIS-RC)、韦氏记忆量表(WMS)及威斯康星卡片分类测定(WCST)等评定,并与正常人组成的对照组进行比较。结果治疗前研究组和治疗组的MMSE、WMS及WAIS-RC均低于对照组,差异有显著性(P〈0.05),提示患者的认知功能有广泛性损害。治疗后研究组MMSE、WCST、WMS、WAIS-RC分数与治疗前比较差异有显著性(P〈0.05),而治疗后治疗组的WCST、WMS、WAIS-RC分数与治疗前比较无显著性差异(P〈0.05)。结论阿尼西坦改善慢性精神分裂症患者的认知功能疗效确切。
Objective To study the curative effect of aniracetam on cognitive impairment in patients with chronic schizophrenia. Methods Sixty-four patients with chronic schizophrenia were randomly assigned to study group（n=32） and treatment group（n=32）. Both groups were treated with quetiapine （350±50）mg/d for eight weeks,study group were treated with aniracetam （1000mg/d） simuhaneoush. Both groups were measured with the Positive and Negative Symptom Scale（PANSS）, the Wechsler Memory Scale（WMS）, Mini-Mental State Examination（MMSE）,Wechsler Adult Intelligence Scale （WAIS-RC） and Wisconsin Card Sorting Test （WCST）. Results Before treatment,the scores of MMSE,WMS and WAIS-RC of both groups were significantly lower than those of normal controls（P〈0.05） . After treatment, scores of MMSE, WCST, WMS and WAISRC in study group had significant improvement,and those in treatment group were on the contrary. （P〉0.05）. Conclusion Aniracetam may improve the cognitive function of chronic schizophenia.
出处
《山东精神医学》
2005年第4期258-259,共2页
Shangdong Archives of Psychiatry
